AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02366741 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Whole brain radiotherapy with reduced dose to the hippocampi
Description: VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
Study NCT01478152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug-like Medical Device: Ectoin Inhalation Solution
Description: After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.~The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose.
Study NCT00599027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Description: Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
Study NCT00599027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: Placebo nasal spray once daily (two puffs per nostril) in the morning.
Study NCT04250012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based ACT intervention
Description: The Internet-based ACT intervention included a 10-week web-based program consisting of five modules with different themes that the participants were instructed to process during the course of two weeks. The program was based on the processes of ACT and included themes such as life values, mindfulness, defusion, self-as-context acceptance and self-compassion. The content of each module consisted of text, video, exercises with audio files, and homework assignments. In addition, the participants filled in a diary with exercises in paper format. The intervention included also three remote meetings (à 45 minutes) via a videoconferencing tool doxy.me conducted by a psychologist. The remote meetings took place at the beginning, after 4 weeks, and at the end of the intervention.
Study NCT04250012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: The psychoeducation group received a self-help booklet and a link to a web-based wellness training program. The program included exercises with MP3 audio files. No personal support during the 10-week intervention was provided.
Study NCT00750165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series CPAP Humidifier
Description: The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
Study NCT02140203 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Training
Description: one-year experimental training (three times per week and one hour per session)
Study NCT03116308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone (OPC)
Description: 50 mg OPC capsules; oral route
Study NCT03329417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task-oriented training
Description: Motor training targeted to goals that are relevant to the functional needs of the patient
Study NCT03329417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task-oriented training
Description: Motor training targeted to goals that are relevant to the functional needs of the patient
Study NCT03627494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3439171A
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study NCT00726154 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: IPSRT
Description: Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
Study NCT00726154 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care
Description: The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
Study NCT02218619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid (TUDCA)
Description: TUDCA at 1750 mg/day x 12 months
Study NCT02218619 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: Placebo
Study NCT03063762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Arms A and B Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an intravenous (IV) infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~Arms C and D Atezolizumab will be administered at a dose of 1200mg as it is a Q3W schedule
Study NCT03063762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Arms A and B Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.~In Arm D, Bevacizumab will be administered at a dose of 15mg/kg on Day 8 of Cycle 2 and on Day 8 of each consecutive cycle.
Study NCT03063762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: Arms A and B RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently. Doses in the extension part will be based on the maximum tolerated dose determined in the escalation part.~In Arms C and D, RO will be administered on Q3W schedule at the dose defined in the dose escalation part
Study NCT01753336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
Study NCT04205370 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deactivated Pregnancy Coach
Description: Naturalistic monitoring of their typical sleep patterns and behaviors
Study NCT04205370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Pregnancy Coach
Description: The Pregnancy Coach will begin to deliver alerts when supine sleep is detected. Sleep metrics will be visible on the smartphone app.
Study NCT00669071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%
Description: Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Study NCT00669071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetaphil® Moisturizing Cream as Inactive Control
Description: Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
Study NCT00539357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES)
Description: Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
Study NCT02219971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kukoamine B Mesilate
Description: Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
Study NCT04375865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2111
Description: celecoxib 200mg
Study NCT04375865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2111
Description: celecoxib 200mg
Study NCT04375865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-2112
Description: Tramadol 150mg
Study NCT04375865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-2112
Description: Tramadol 150mg
Study NCT03692143 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: subcutaneous injection of teriparatide(20 mg) once daily
Study NCT03309982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant polyphenol blend
Description: A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
Study NCT03309982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
Study NCT04593550 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04593550 — intervention group
Intervention type: BEHAVIORAL
Intervention: BrainCheck Cognitive Assessment
Description: Undergo cognitive function assessment BrainCheck
Study NCT04593550 — intervention group
Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Undergo 3D-Confusion assessment
Study NCT04593550 — intervention group
Intervention type: PROCEDURE
Intervention: Electroencephalography
Description: Undergo EEG
Study NCT02558101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control invitation materials
Description: In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:~1. a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes~2. an invitation letter with a pre-scheduled appointment plus the same information booklet~3. a reminder re-invitation letter for those who miss their appointment without cancelling
Study NCT02558101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention invitation materials
Description: The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
Study NCT03445767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MedSafer
Description: An electronic deprescribing intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation. These recommendations are presented to the treating physicians for their consideration.
Study NCT00920998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-338
Description: oral
Study NCT01571622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey before Breakfast
Description: After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
Study NCT01571622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey before Breakfast
Description: After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
Study NCT01571622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water before breakfast
Description: After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
Study NCT01571622 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water before breakfast
Description: After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
Study NCT04631809 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
Study NCT04631809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT-Coronary Angiography + Coronary angiography +/- percutaneous coronary intervention
Description: Comparison of performing invasive Coronary Angiography alone with performing CT-Coronary Angiography prior to the invasive Coronary Angiography
Study NCT05158920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy for Suicidal individuals (MBCT-S)
Description: MBCT-S is a group intervention of 8 weekly sessions of 2 hours combining techniques of mindfulness with important elements of cognitive therapy (e.g. safety plan and homework).
Study NCT03692143 — intervention group
Intervention type: PROCEDURE
Intervention: PVP
Description: With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously
Study NCT03692143 — intervention group
Intervention type: DRUG
Intervention: Alendronate
Description: Alendronate Sodium, oral, 70mg, once a week
Study NCT01403974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Intravenous infusion once every week
Study NCT03428724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Preparation
Description: standard PEG-based bowel preparation for colonoscopy (either split dose 4L polyethylene glycol or split 2L PEG + ascorbic acid)
Study NCT03428724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized Preparation
Description: individualized bowel preparation for colonoscopy (either split dose 4L PEG or split 2L PEG + ascorbic acid) based o patient characteristics (history of failed bowel preparation; use of laxative drugs, increased BMI, age>65, neurologic comorbidities)
Study NCT02499822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Description: Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
Study NCT02499822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
Study NCT03896386 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Use of seizure diary
Description: The participants will press the alert button when they witness and alerting behaviour on their dogs or the Seizure button when they had experienced a seizure. We will receive this information live through the app back-end
Study NCT03390816 — intervention group
Intervention type: OTHER
Intervention: Nutritional assessment
Description: Observational
Study NCT04269252 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CHI-907
Description: CHI-907 is a high CBD extract.
Study NCT04269252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CHI-804
Description: CHI-804 is the placebo formulation.
Study NCT01703039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Study NCT01703039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Study NCT01703039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study NCT01703039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT01523535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: repeated cycles of short sleep
Description: - 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
Study NCT01523535 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: repeated cycles of short sleep
Description: - 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
Study NCT05799742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral hernioplasty
Study NCT02787031 — intervention group
Intervention type: PROCEDURE
Intervention: Neuraxial anesthesia
Study NCT02787031 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Study NCT02009215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
Study NCT01692483 — intervention group
Intervention type: DRUG
Intervention: Abiraterone acetate
Description: Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
Study NCT01692483 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: Prednisone or prednisolone 5 mg tablet taken orally twice daily
Study NCT00698919 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.~The new techniques used (DNA detection) will done later on and thus won't modify their decision.
Study NCT02545738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: active treatment
Study NCT03627494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study NCT00886574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 200 mg (50 mg 2T twice per day)
Study NCT00886574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 100 mg once a day
Study NCT03592342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
Study NCT03592342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobetasol Propionate
Description: Rivelin® patch is a two-layer patch comprised of a muco-adhesive, drug-delivery layer and a protective layer.
Study NCT03594695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HSCRP and NLR
Description: hs-CRP levels and NLR values will be studied from routine blood samples.
Study NCT01834430 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition
Study NCT02925585 — intervention group
Intervention type: OTHER
Intervention: Pre/post imaging
Study NCT03056261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined general and epidural
Description: Combined general and epidural anaesthesia
Study NCT03056261 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: General anaesthesia
Description: General anaesthesia
Study NCT01237353 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: betaine hydrochloride
Description: betaine hydrochloride 1500mg po x 1 on day 5
Study NCT01237353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: rabeprazole po daily x 5 days
Study NCT04570397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Patients will receive weight-based dosing of ravulizumab on Days 1, 5, 10, and 15 along with the standard care.
Study NCT04449757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicarbonated Ringer's solution
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Study NCT04449757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Description: Method of administration: intravenous infusion; 500-1000ml each time; Speed of infusion: it is decided by the clinicians.
Study NCT01530594 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide/Low dose Dex
Description: Lenalidomide/Low dose Dex (LLD)